Drug Utilization Review Board Meeting

September 18, 2014

Therapeutic Class	Drug Name	Current PDL Status	DCH Decisions
Drug Reviews			
Estrogens-Selective Estrogen Receptor Modifiers			
	Duavee (Oral) Tablet	NP/PA	NP/PA
	Cenestin (Oral) Tablet	NP	P
	Activella (Oral) Tablet	NP	P
	Raloxifene (Oral) Tablet	NP/PA	P
	Estrace (Oral) Tablet	P	NP/PA
	Evista (Oral) Tablet	P	NP/PA
	Minivelle (Transdermal) Patch	P	NP/PA
Antidiabetics – Non-Insulin			
	Farxiga (Oral) Tablet	NP/PA	NP/PA
Antineoplastics – Enzyme Inhibitors for Acute Lymphocytic Leukemia (ALL) and Chronic Myelogenous Leukemia (CML)			
	Iclusig (Oral) Tablet	P/PA	P/PA
Dermatologics - Antifungals			
	Luzu (Topical) Cream	NP/PA	NP/PA
	Econazole (Topical) Cream	NP/PA	P
	Nystatin-Triamcinolone (Topical) Cream	P	NP/PA
	Nystatin-Triamcinolone (Topical) Ointment	P	NP/PA
Phosphate Binder Agents			
	Velphoro (Oral) Tablet Chew	NP/PA	NP/PA
Analgesics, Opioid Long-Acting			
	Zohydro ER (Oral) Capsule	NP/PA	NP/PA

Antibiotics - Macrolides			
	Ery-Tab (Oral) Tablet	P	NP/PA
	EES 400 (Oral) Tablet	P	NP/PA
	Erythrocin (Oral) Tablet	P	NP/PA
	Erythromycin (Oral) Tablet	P	NP/PA
	PCE (Oral) Tablet	P	NP/PA
	Erythromycin (Oral) Capsule	P	NP/PA
	EryPed 200 (Oral) Suspension	P	NP/PA
	EryPed 400 (Oral) Suspension	P	NP/PA
Antifungals - Oral			
	Terbinafine (Oral) Tablet	P/PA	P
	Sporanox (Oral) Solution	NP/PA	P/PA
Antihistamines - Oral			
	Levocetirizine (Oral) Tablet	NP/PA	P
	Arbinoxa (Oral) Tablet	P	NP/PA
	Arbinoxa (Oral) Liquid	P	NP/PA
	Clarinex (Oral) Syrup	P/PA	NP/PA
	Clarinex (Oral) Tablet	P/PA	NP/PA
Antivirals – Genital Herpes Agents			
	Acyclovir (Topical) Ointment	NP/PA	P
	Zovirax (Topical) Ointment	P	NP/PA
Dermatologics – Genital Warts			
	Aldara (Topical) Cream	NP	P
	Imiquimod (Topical) Cream	P	NP/PA
Gastrointestinal, Ulcer Drugs – Histamine-2 (H-2) Antagonists			
	Nizatidine (Oral) Capsule	P	NP/PA

	Nizatidine (Oral) Solution	P	NP/PA
Immunosuppressive Agents for Organ Transplant Rejection			
	Sirolimus (Oral) Tablet	NP/PA	P
	Rapamune (Oral) Tablet	P	NP/PA
Skeletal Muscle Relaxants			
	Metaxalone (Oral) Tablet	NP/PA	NP
	Carisoprodol Compound-Codeine (Oral) Tablet	P	NP/PA
	Skelaxin (Oral) Tablet	NP	NP/PA

NP = non-preferred/ P = preferred/ PA = prior authorization

Clinical Review

The Department of Community Health will follow the 2014 American Academy of Pediatrics Policy Statement on the Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection for Synagis prior authorization criteria.